Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990)
Hong Kong
· Delayed Price · Currency is HKD
161.50
-4.10 (-2.48%)
Nov 15, 2024, 9:30 AM HKT
Sichuan Kelun-Biotech Biopharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -232.78 | -574.13 | -616.1 | -889.8 |
| Depreciation & Amortization | 83.58 | 75.08 | 67.36 | 22.91 |
| Loss (Gain) From Sale of Assets | 1.49 | 1.49 | -5.42 | 0.01 |
| Loss (Gain) From Sale of Investments | -10.53 | -10.53 | -0.51 | -0.36 |
| Stock-Based Compensation | 123.35 | 123.35 | 19.81 | 6.5 |
| Other Operating Activities | -721.05 | 168.8 | 229.49 | 95.71 |
| Change in Accounts Receivable | -124.37 | -124.37 | -20.13 | 0.24 |
| Change in Inventory | -10.4 | -10.4 | 26.07 | -37.28 |
| Change in Accounts Payable | 252.62 | 252.62 | 50.57 | 90.67 |
| Change in Unearned Revenue | 294.34 | 294.34 | 6.2 | 109.04 |
| Change in Other Net Operating Assets | -136.67 | -136.67 | -28.2 | 116.42 |
| Operating Cash Flow | -480.43 | 59.56 | -270.85 | -485.94 |
| Capital Expenditures | -84.07 | -80.98 | -33.66 | -94.08 |
| Sale of Property, Plant & Equipment | 0.02 | 0.01 | 6.33 | - |
| Sale (Purchase) of Intangibles | -2.33 | -1.27 | -5.33 | -0.66 |
| Investment in Securities | 272.32 | -943.17 | 0.51 | 0.36 |
| Investing Cash Flow | 185.94 | -1,025 | -32.15 | -94.38 |
| Short-Term Debt Issued | - | - | 363 | 225.48 |
| Total Debt Issued | - | - | 363 | 225.48 |
| Short-Term Debt Repaid | - | -394.04 | -45 | -70 |
| Long-Term Debt Repaid | - | -66.76 | -1.62 | -1.99 |
| Total Debt Repaid | -49.47 | -460.8 | -46.62 | -71.99 |
| Net Debt Issued (Repaid) | -49.47 | -460.8 | 316.38 | 153.49 |
| Issuance of Common Stock | 1,864 | 2,853 | - | 533.81 |
| Other Financing Activities | -6.31 | -10.01 | -2.93 | -39.99 |
| Financing Cash Flow | 1,808 | 2,382 | 313.45 | 647.32 |
| Foreign Exchange Rate Adjustments | 29.52 | 19.39 | 0.71 | -1.39 |
| Net Cash Flow | 1,543 | 1,436 | 11.17 | 65.6 |
| Free Cash Flow | -564.5 | -21.42 | -304.51 | -580.03 |
| Free Cash Flow Margin | -30.07% | -1.39% | -37.88% | -1794.52% |
| Free Cash Flow Per Share | -2.59 | -0.12 | -3.19 | -6.27 |
| Cash Interest Paid | 6.31 | 10.01 | 2.93 | 39.99 |
| Levered Free Cash Flow | -2,425 | -438.58 | -174.83 | - |
| Unlevered Free Cash Flow | -2,420 | -385.88 | -81.82 | - |
| Change in Net Working Capital | 2,425 | 218.49 | -116.22 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.